Last reviewed · How we verify
NAs+IFN-α
NAs+IFN-α combines nucleos(t)ide analogues with interferon-alpha to suppress hepatitis B virus replication and enhance antiviral immune response.
NAs+IFN-α combines nucleos(t)ide analogues with interferon-alpha to suppress hepatitis B virus replication and enhance antiviral immune response. Used for Chronic hepatitis B infection.
At a glance
| Generic name | NAs+IFN-α |
|---|---|
| Sponsor | Beijing 302 Hospital |
| Drug class | Antiviral combination therapy |
| Target | Hepatitis B virus reverse transcriptase; interferon-alpha receptor signaling |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
Nucleos(t)ide analogues (NAs) directly inhibit hepatitis B virus reverse transcriptase, reducing viral replication. Interferon-alpha (IFN-α) is an immunomodulatory cytokine that enhances innate and adaptive immune responses against HBV-infected hepatocytes. The combination approach targets both viral suppression and immune activation for chronic hepatitis B treatment.
Approved indications
- Chronic hepatitis B infection
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Hematologic abnormalities (leukopenia, thrombocytopenia)
- Elevated liver enzymes
- Depression/mood changes
- Headache
Key clinical trials
- The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients (NA)
- A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B
- Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients (NA)
- Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT） (PHASE4)
- Pegylated Interferon α in Previously Interferon-treated CHB（Leading Study） (NA)
- A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B (PHASE3)
- To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs. (NA)
- Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NAs+IFN-α CI brief — competitive landscape report
- NAs+IFN-α updates RSS · CI watch RSS
- Beijing 302 Hospital portfolio CI